Table 1. Results of association analyses in patients with CM-SJS/TEN with SOC.
| Carrier frequency (%) | Dominant model analysis | Gene frequency (%) | Dominant model analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Odds ratio | Odds ratio | ||||||||||
| ethnic group | HLA genotype | CM-SJS/TEN with SOC | Control | P | Pc | (95% CI) | CM-SJS/TEN with SOC | Control | P | Pc | (95% CI) |
| Indian | A*02:06 | 1/20 (5.0%) | 3/55 (5.5%) | 0.938 | - | 0.91 (0.09–9.31) | 1/39 (2.5%) | 3/110 (2.7%) | 0.939 | - | 0.91 (0.09–9.06) |
| B*44:03 | 12/20 (60.0%) | 6/55 (10.9%) | 1.07.E-05 | 2.14.E-05 | 12.25 (3.57–42.01) | 17/40 (42.5%) | 7/110 (6.4%) | 9.37.E-08 | 1.87.E-07 | 10.88 (4.04–29.3) | |
| Brazilian | A*02:06 | 0/39 (0.00%) | 0/134 (0.00%) | - | - | - | 0/78 (0.00%) | 0/268 (0.00%) | - | - | - |
| B*44:03 | 10/39 (25.6%) | 15/134 (11.2%) | 0.0239 | 0.0478 | 2.74 (1.12–6.71) | 11/78 (14.1%) | 15/268 (5.60%) | 0.0121 | 0.0242 | 2.77 (1.22–6.31) | |
| Korean | A*02:06 | 11/31 (35.5%) | 14/90 (15.6%) | 0.0181 | 0.0362 | 3.00 (1.18–7.57) | 12/62 (19.4%) | 16/180 (8.9%) | 0.0263 | 0.0526 | 2.46 (1.09–5.54) |
| B*44:03 | 6/31 (19.4%) | 18/90 (20.0%) | 0.938 | - | 0.96 (0.34–2.69) | 7/62 (11.3%) | 19/180 (10.6%) | 0.872 | - | 1.07 (0.43–2.70) | |
P: P values obtained with the χ2-test (Pearson), CI: Confidence interval.
Pc: P values corrected for the multiplicity of testing by the number of comparisons 2 (HLA-A*02:06 + HLA-B*44:03).
CM-SJS/TEN: cold medicine-related SJS/TEN, SOC: severe ocular surface complications.